Berenberg trims Novo Nordisk view as Eli Lilly’s oral pipeline shifts focus to pills

Eli Lilly’s push toward oral weight-loss and diabetes therapies is reshaping how some analysts frame competition in the booming GLP-1 drug class, according to a market update circulated by Yahoo Finance on Aug. 12, 2026.

The update points to a Berenberg reassessment of Novo Nordisk, suggesting that the previous upside case tied to a pill version of Novo’s blockbuster weight-loss drug Wegovy has already largely been “played out.” In the same framing, Berenberg appears to shift incremental expectations to Eli Lilly’s efforts to win share in the oral segment.

While the market narrative has centered on injections, an oral option matters because it can change how payers and patients think about access and convenience. The Yahoo Finance update characterizes the competitive picture as moving from “how big is the pill opportunity” to “who benefits most if the oral market scales.”

Berenberg’s positioning, as summarized in the Yahoo Finance item, implies that valuation and sentiment for Novo Nordisk are less dependent on the near-term prospect of Wegovy tablets than they were previously. The update also states that, in Berenberg’s view, the valuation multiple for Novo is now around the “European pharma average,” pointing to less enthusiasm than investors previously priced in.

The GLP-1 sector has undergone rapid expectation shifts over the past two years as companies have raced to differentiate on efficacy, tolerability, dosing convenience, and manufacturing scale. Oral GLP-1 programs are generally treated as a potential accelerant because a tablet could lower the friction of long-term use compared with injections, potentially expanding the addressable market.

Eli Lilly, which is the named beneficiary in the Berenberg framing, has become a focal point for investors watching whether an oral format can deliver comparable benefit while maintaining acceptable safety and adherence. The Yahoo Finance item does not provide detailed trial readouts in the excerpt used for this editorial packet, but it does connect Lilly’s oral strategy to a rebalancing of competitive expectations within the space.

What is not clear from the Yahoo Finance summary is the specific magnitude of Berenberg’s adjustment, such as any numerical changes to targets, price objectives, or formal rating labels. The update also does not disclose timing details for oral product commercialization, nor does it cite particular clinical endpoints in the excerpt provided.